Dose-dependent relation between metformin and the risk of hormone receptor-positive, her2-negative breast cancer among postmenopausal women with type-2 diabetesSoumya Chikermane, Michael L. Johnson, Meghana V. Trivedi et al.|Breast Cancer Research and Treatment|2022Cited by 17
Abstract 4364: Cost-effectiveness analysis of abemaciclib and endocrine therapy combination for the adjuvant treatment of HR+/HER2-, node-positive, high-risk, early breast cancerAshna Talwar, Rajender R. Aparasu, Ashish A. Deshmukh et al.|Cancer Research|2023Cited by 3
1051 Prediction of severe immune-related adverse events among real-world patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: a SEER-medicare analysisOlajumoke A. Olateju, J. Douglas Thornton, Rajender R. Aparasu et al.|Regular and Young Investigator Award Abstracts|2025Cited by 0
Predictors of severe immune-related adverse events during first-line immune checkpoint inhibitor therapy for advanced non-small cell lung cancerOlajumoke A. Olateju, J. Douglas Thornton, Rajender R. Aparasu et al.|Scientific Reports|2026Cited by 0
Safety and effectiveness of immune checkpoint inhibitors in older adults with metastatic non-small cell lung cancer and pre-existing autoimmune disease – A SEER-Medicare studyShrey Gohil, Michael L. Johnson, Whitney E. Lewis et al.|Journal of Geriatric Oncology|2026Cited by 0